Xuanwu Hospital
首都医科大学宣武医院
Listed for 20 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Xuanwu Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Hepatocellular carcinoma肝细胞癌15 papers led
- Stomach cancer胃癌5 papers led
- Retinoblastoma视网膜母细胞瘤0 papers led
- Chordoma脊索瘤7 papers led
- Osteosarcoma骨肉瘤1 paper led
- Neuroblastoma神经母细胞瘤3 papers led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led
- Beta thalassaemiaβ 地中海贫血1 paper led
- Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
- Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病5 papers led2 open trials led
- IgG4-related diseaseIgG4相关性疾病2 papers led
- Myasthenia gravis重症肌无力16 papers led1 open trial led
- Moyamoya disease烟雾病7 papers led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎9 papers led
- Takayasu arteritis大动脉炎6 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症7 papers led
- Duchenne muscular dystrophy杜氏肌营养不良1 paper led
- Behçet disease白塞病0 papers led
- IgA nephropathyIgA 肾病2 papers led
- Niemann–Pick disease type C尼曼-匹克病 C 型1 paper led
Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatoblastoma, Gastrointestinal stromal tumour, Ewing sarcoma, Multiple myeloma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Wilson disease, Biliary atresia, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Alport syndrome, Gaucher disease, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Hepatocellular carcinoma
肝细胞癌Led 15 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
17 hospitals in Beijing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led15
- Preoperative prediction of Glypican-3 in hepatocellular carcinoma by two-dimensional ultrasound, contrast-enhanced ultrasound and microflow imaging.
- Machine learning-based tumor associated macrophages polarity signature predicts prognosis and treatment response in hepatocellular carcinoma.
- Hypoxia-Activated Imidazoquinoline Prodrug Nanoparticles Potentiate Radiofrequency Ablation-Mediated Antitumor Immunity Against Hepatocellular Carcinoma.
- Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma-
- Diagnostic values of contrast-enhanced MRI and contrast-enhanced CT for evaluating the response of hepatocellular carcinoma after transarterial chemoembolisation: a meta-analysis.
- The value of contrast-enhanced ultrasound combined with microflow imaging in predicting microvascular invasion of hepatocellular carcinoma before operation.
- Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysis.
- Developments and current status of cell-free DNA in the early detection and management of hepatocellular carcinoma.
- Comprehensive analysis of anoikis-related lncRNAs for predicting prognosis and response of immunotherapy in hepatocellular carcinoma.
- Intratumoral perfusion may affect microwave ablation area of hepatocellular carcinoma.
- Clinical efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis.
- Exploration and validation of the prognostic value of RNA-binding proteins in hepatocellular carcinoma.
- Fluorescent Imaging-Guided Chemo- and Photodynamic Therapy of Hepatocellular Carcinoma with HCPT@NMOFs-RGD Nanocomposites.
- Identification and validation of ADME genes as prognosis and therapy markers for hepatocellular carcinoma patients.
- Blockade of Erythropoietin-Producing Human Hepatocellular Carcinoma Receptor B1 in Spinal Dorsal Horn Alleviates Visceral Pain in Rats.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status1
Cancer
Stomach cancer
胃癌Led 5 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.05%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
15 hospitals in Beijing for stomach cancer218 hospitals in China for stomach cancer
No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led5
- Effect of perioperative immunonutrition on outcomes in gastric cancer surgery patients: A systematic review and evidence map.
- Do serum biomarkers correlate to the risk of gastric lesions in patients with autoimmune gastritis༟-A systematic review and meta-analysis.
- PTPRG-AS1 regulates the KITLG/KIT pathway through the ceRNA axis to promote the malignant progression of gastric cancer and the intervention effect of Compound Kushen injection on it.
- Identification of critical prognosis signature associated with lymph node metastasis of stomach adenocarcinomas.
- Deep learning as a novel method for endoscopic diagnosis of chronic atrophic gastritis: a prospective nested case-control study.
Cancer
Retinoblastoma
视网膜母细胞瘤Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Beijing for retinoblastoma196 hospitals in China for retinoblastoma
No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Cancer
Chordoma
脊索瘤Led 7 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 6.7%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Beijing for chordoma88 hospitals in China for chordoma
No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led7
- Pitfalls and strategies of CAR-T therapy in solid tumors and implications for chordoma treatment.
- The efficacy and safety of tyrosine kinase inhibitors in the treatment of advanced or metastatic chordoma: a single-arm meta-analysis.
- Single-cell sequencing reveals VEGFR as a potential target for CAR-T cell therapy in chordoma.
- Interleukin-7 expression by CAR-T cells improves CAR-T cell survival and efficacy in chordoma.
- Linc01116 Silencing Inhibits the Proliferation and Invasion, Promotes Apoptosis of Chordoma Cells via Regulating the Expression of Mir-9-5p/PKG1.
- Single-cell transcriptome profiling reveals intra-tumoral heterogeneity in human chordomas.
- Surgical Outcomes of Clival Chordoma Through Endoscopic Endonasal Approach: A Single-Center Experience.
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status2
Cancer
Osteosarcoma
骨肉瘤Led 1 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.04%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
48 hospitals in Beijing for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Cancer
Neuroblastoma
神经母细胞瘤Led 3 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
24 hospitals in Beijing for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Enhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma.
- NMDA Receptor GluN2B Subunit Is Involved in Excitotoxicity Mediated by Death-Associated Protein Kinase 1 in Alzheimer's Disease.
- Carnosic Acid Attenuates AβOs-Induced Apoptosis and Synaptic Impairment via Regulating NMDAR2B and Its Downstream Cascades in SH-SY5Y Cells.
Earlier papers (2016–2020)1
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Beijing for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia
No open trial on B-cell acute lymphoblastic leukaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Beta thalassaemia
β 地中海贫血Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Beijing for beta thalassaemia157 hospitals in China for beta thalassaemia
No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Thrombotic thrombocytopenic purpura
血栓性血小板减少性紫癜Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Beijing for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura
No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病Led 5 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 1.0%.
- Open trials as a site
- 0
- led by another institution
12 hospitals in Beijing for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSD
- Phase
- Not given
- Started
- 2026-07
- Registry
- NCT07762872
Age 18 years to Not stated (registered criteria)
Led by Xuanwu HospitalBeijing
- Not yet recruitingUniversal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
- Phase
- Early phase 1
- Started
- 2025-02
- Registry
- NCT06485232
Age 18 years to 75 years (registered criteria)
Led by Xuanwu HospitalBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led5
- Progressive brain function changes in patients with neuromyelitis optica: insights from resting-state fMRI.
- Changes in brain functional connectivity and clinical correlations in neuromyelitis optica spectrum disorder: a longitudinal resting-state fMRI study.
- Factors influencing the degree of disability in patients with neuromyelitis optica spectrum disorders.
- Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS.
- Multi-parametric MRI phenotype with trustworthy machine learning for differentiating CNS demyelinating diseases.
All its trials on ClinicalTrials.gov, any status7
- Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
- Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders
- An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients
- National, Multicentric Registry Study on Neuroimmunological Diseases in China
- Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders
- A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSD
- Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Other diseases
IgG4-related disease
IgG4相关性疾病Led 2 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Beijing for IgG4-related disease46 hospitals in China for IgG4-related disease
No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led2
Chinese-language papers (not in the count)1
Other diseases
Myasthenia gravis
重症肌无力Led 16 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 3.2%.
11 hospitals in Beijing for myasthenia gravis93 hospitals in China for myasthenia gravis
Open trials with this hospital 4
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingUniversal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
- Phase
- Early phase 1
- Started
- 2025-02
- Registry
- NCT06485232
Age 18 years to 75 years (registered criteria)
Led by Xuanwu HospitalBeijing
- RecruitingMyasthenia Gravis Registry in China
- Phase
- Not given
- Started
- 2024-02
- Registry
- NCT06241521
Age not stated (registered criteria)
Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou
- RecruitingEfficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Phase
- Phase 3
- Started
- 2024-06
- Registry
- NCT06463587
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou, Zunyi
- RecruitingA Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Phase
- Phase 3
- Started
- 2021-07
- Registry
- NCT04951622
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led16
- Dynamic Changes in Peripheral Immune Cells During Efgartigimod Treatment in Naive Generalized Myasthenia Gravis.
- Peripheral immune profiling highlights a dynamic role of low-density granulocytes in myasthenia gravis.
- Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study.
- Platelet activation plays a pro-inflammatory role in myasthenia gravis.
- Myasthenia gravis due to anti-PD-1 treatment for an advanced colon cancer patient: a case report and literature review.
- Integrative multi-omics analysis identifies genetically supported druggable targets and immune cell specificity for myasthenia gravis.
- Environmental factors affecting the risk of generalization for ocular-onset myasthenia gravis: a nationwide cohort study.
- Mortality of myasthenia gravis: a national population-based study in China.
- Comparison between mono-tacrolimus and mono-glucocorticoid in the treatment of myasthenia gravis.
- Genetically predicted effects of physical activity and sedentary behavior on myasthenia gravis: evidence from mendelian randomization study.
- Autoantibody levels as biomarkers of disease activity in the management of myasthenia gravis.
- Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study.
- A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis.
- Involvement of Ocular Muscles in Patients With Myasthenia Gravis With Nonocular Onset.
- CYP3A5*3 polymorphism and age affect tacrolimus blood trough concentration in myasthenia gravis patients.
- Risk Factors for Postoperative Myasthenic Crisis After Thymectomy in Patients With Myasthenia Gravis.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status8
- Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
- National, Multicentric Registry Study on Neuroimmunological Diseases in China
- Clinical Prognosis and Progression of Myasthenia Gravis Patients
- Myasthenia Gravis Registry in China
- Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
- Study of Telitacicept in Generalized Myasthenia Gravis
Other diseases
Moyamoya disease
烟雾病Led 7 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 2.0%.
- Open trials led
- 0
- recruiting or about to
8 hospitals in Beijing for moyamoya disease47 hospitals in China for moyamoya disease
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingDevelopment and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07894107
Age 12 years to 70 years (registered criteria)
Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou
- RecruitingRegistry of Multicenter Brain-Heart Comorbidity in China
- Phase
- Not given
- Started
- 2012-01
- Registry
- NCT05961748
Age 18 years to Not stated (registered criteria)
Led by Beijing Tiantan Hospital; 4 listed hospitals as study sitesBeijing, Harbin, Shanghai, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led7
- The Role of TCD in Assessing Postoperative Collateral Development and Long-Term Clinical Outcome in Moyamoya Disease.
- Remote ischemic conditioning prevents ischemic cerebrovascular events in children with moyamoya disease: a randomized controlled trial.
- Imaging features of adult moyamoya disease patients with anterior intracerebral hemorrhage based on high-resolution magnetic resonance imaging.
- Characteristics of cerebral ischemic stroke based on moyamoya disease and atherosclerosis-associated intracranial arterial stenosis.
- Vascular Architecture Characters and Changes of Pediatric Moyamoya Disease after Combined Bypass Surgery.
- Pathophysiological Significance of Neutrophilic Transfer RNA-Derived Small RNAs in Asymptomatic Moyamoya Disease.
- Validation of choroidal anastomosis on high-resolution magnetic resonance imaging as an imaging biomarker in hemorrhagic moyamoya disease.
All its trials on ClinicalTrials.gov, any status4
- The Safety and Efficacy of RIC on Adult Moyamoya Disease
- The Effect of RIC on TIA/Stroke in Children With Moyamoya Disease
- Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
- Registry of Multicenter Brain-Heart Comorbidity in China
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 9 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 3.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
13 hospitals in Beijing for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led9
- Clinical characterization of diseases associated with anti-N-methyl-D-aspartate receptor encephalitis combined with anti-myelin oligodendrocyte glycoprotein antibodies in adults.
- Psychiatric features in NMDAR and LGI1 antibody-associated autoimmune encephalitis.
- Clinical features of COVID-19-related encephalitis: comparison with the features of herpes virus encephalitis and autoimmune encephalitis.
- Status dystonicus in adult patients with anti-N-methyl-D-aspartate-acid receptor encephalitis.
- Characteristics and Outcomes of Paroxysmal Sympathetic Hyperactivity in Anti-NMDAR Encephalitis.
- Focal motor seizure as a presenting symptom in anti-mGluR5 encephalitis: A case report.
- Clinical efficacy of plasma exchange in patients with autoimmune encephalitis.
- Presence of Anti-Thyroid Antibodies Correlate to Worse Outcome of Anti-NMDAR Encephalitis.
- Overlapping syndrome of anti-N-methyl-D-aspartate receptor encephalitis and anti-myelin oligodendrocyte glycoprotein inflammatory demyelinating diseases: A distinct clinical entity?
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)6
- AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) coexisting with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: A case report and literature review.
- Efficacy of Therapeutic Plasma Exchange in Patients with Severe Refractory Anti-NMDA Receptor Encephalitis.
- Reply.
- Clinical Characteristics and Prognosis of Severe Anti-N-methyl-D-aspartate Receptor Encephalitis Patients.
- Analysis of electroencephalogram characteristics of anti-NMDA receptor encephalitis patients in China.
- [Analysis of clinical characteristics and outcomes of mechanically ventilated patients with anti-N-methyl-D-aspartate receptor encephalitis].
Other diseases
Takayasu arteritis
大动脉炎Led 6 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 3.2%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
30 hospitals in Beijing for Takayasu arteritis108 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led6
- An update on stroke and transient ischemic attack in Takayasu arteritis: A systematic review and meta-analysis.
- Clinical value of diagnosing ischaemic stroke in patients with Takayasu's arteritis combining multiple arterial occlusion and high-grade enhancement.
- Cerebral Perfusion Features in Takayasu Arteritis: Insights From pCASL MRI.
- Childhood-onset versus adult-onset Takayasu arteritis: A study of 239 patients from China.
- Long-term outcomes of angioplasty for pediatric renovascular hypertension: A single-center experience.
- Covered Cheatham-Platinum Stent for Treatment of Descending Thoracic Aortic Stenosis Caused by Takayasu Arteritis in Two Children.
Earlier papers (2016–2020)2
All its trials on ClinicalTrials.gov, any status5
- Remote Ischemic Conditioning for Cerebral Ischemia in Patients With Takayasu Arteritis (TARIC-1)
- Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis
- Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis
- A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)
- Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 7 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.9%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
19 hospitals in Beijing for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led7
- Characterization and chemoproteomic profiling of protein O-GlcNAcylation in SOD1-G93A mouse model.
- Different baseline functional patterns of the frontal cortex in amyotrophic lateral sclerosis patients with Corticospinal tract hyperintensity.
- Proteomics analysis indicates the involvement of immunity and inflammation in the onset stage of SOD1-G93A mouse model of ALS.
- Identification of TARDBP Gly298Ser as a founder mutation for amyotrophic lateral sclerosis in Southern China.
- Different sensorimotor mechanism in fast and slow progression amyotrophic lateral sclerosis.
- The associations between plasma soluble Trem1 and neurological diseases: a Mendelian randomization study.
- Unusual electrophysiological findings in a Chinese ALS 4 family with SETX-L389S mutation: a three-year follow-up.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)8
- Rare, low-frequency and common coding variants of ARHGEF28 gene and their association with sporadic amyotrophic lateral sclerosis.
- Mendelian randomization study to evaluate the effects of interleukin-6 signaling on four neurodegenerative diseases.
- Activation of the Notch Signaling Pathway and Cellular Localization of Notch Signaling Molecules in the Spinal Cord of SOD1-G93A ALS Model Mice.
- The Role of Iron in Amyotrophic Lateral Sclerosis.
- Presence of antibodies against low-density lipoprotein receptor-related protein 4 and impairment of neuromuscular junction in a Chinese cohort of amyotrophic lateral sclerosis.
- The efficacy and safety of riluzole for neurodegenerative movement disorders: a systematic review with meta-analysis.
- Total intravenous anesthesia without muscle relaxant in a parturient with amyotrophic lateral sclerosis undergoing cesarean section: A case report.
- Atypical familial amyotrophic lateral sclerosis with initial symptoms of pain or tremor in a Chinese family harboring VAPB-P56S mutation.
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Beijing for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy
No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Other diseases
Behçet disease
白塞病Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
24 hospitals in Beijing for Behçet disease149 hospitals in China for Behçet disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- Phase
- Phase 3
- Started
- 2023-11
- Registry
- NCT06145893
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
Other diseases
IgA nephropathy
IgA 肾病Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
32 hospitals in Beijing for IgA nephropathy346 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Other diseases
Niemann–Pick disease type C
尼曼-匹克病 C 型Led 1 of the 16 English-language PubMed papers on Niemann–Pick disease type C with an author in mainland China, 2021–2025: 6.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Beijing for Niemann–Pick disease type C15 hospitals in China for Niemann–Pick disease type C
No open trial on Niemann–Pick disease type C lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other linked evidence
Getting in touch
Name card to show staff or a driver
首都医科大学宣武医院
Xuanwu Hospital
北京
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
No hospital-level ROR record matched.
Xuanwu Hospital of Capital Medical University; Xuanwu Hospital Capital Medical University; XuanWu hospital; Xiongan Xuanwu Hospital; Beijing Xuanwu Hospital; Xuanwu Hospital (S.H; Neurology of Xuanwu Hospital; Xuanwu Hospital (S.L.)